Who are Placebo to Benralizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Benralizumab Prefilled Syringe, Fasenra®, Benralizumab Arm C.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-benralizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo to Benralizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Benralizumab (Placebo to Benralizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-5 receptor alpha subunit antagonist. Area: Respiratory.

phase 3 IL-5 receptor alpha subunit antagonist IL-5Rα Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Placebo to Benralizumab (Placebo to Benralizumab) — AstraZeneca. Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit, leading to the depletion of eosinophils.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Benralizumab TARGET	Placebo to Benralizumab	AstraZeneca	phase 3	IL-5 receptor alpha subunit antagonist	IL-5Rα
Benralizumab Prefilled Syringe	Benralizumab Prefilled Syringe	Nantes University Hospital	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
Benralizumab Arm C	Benralizumab Arm C	AstraZeneca	phase 3	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-5 receptor alpha subunit antagonist class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Benralizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-benralizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab